diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13088diaendo-13088Research ArticleОригинальные исследованияOriginal StudiesЭндотелиальная дисфункция у лиц с ожирением при наличии и отсутствии сахарного диабета 2 типа: оценка специфических маркеровEndothelial dysfunction in patients with obesity and type 2 diabetes mellitus or normoglycemia: assessment of specific markershttps://orcid.org/0000-0001-5268-430XПокровскаяЕ. В.PokrovskayaE. V.

Покровская Елена Владиславовна – научный сотрудник.

117036, Москва, ул. Дм. Ульянова, д. 11

Elena V. Pokrovskaya - research associate.

11 Dm. Ulyanova street, 117036 Moscow

pokrovskaya.93@mail.ruhttps://orcid.org/0000-0001-6612-6851ШестаковаЕ. А.ShestakovaE. A.

Шестакова Екатерина Алексеевна - доктор медицинских наук, ведущий научный сотрудник.

Москва

Ekaterina A. Shestakova - MD, PhD, leading research associate.

Moscow

katiashestakova@mail.ruhttps://orcid.org/0000-0002-5057-127XШестаковаМ. В.ShestakovaM. V.

Шестакова Марина Владимировна – доктор медицинских наук, профессор, академик РАН.

Москва

Marina V. Shestakova - MD, PhD, Professor.

Moscow

nephro@endocrincentr.ruГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии»РоссияEndocrinology Research CentreRussian Federation202322102023265439445Copyright © Покровская Е.В., Шестакова Е.А., Шестакова М.В., 20232023Покровская Е.В., Шестакова Е.А., Шестакова М.В.Pokrovskaya E.V., Shestakova E.A., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13088ОБОСНОВАНИЕ

ОБОСНОВАНИЕ. Одной из важнейших функций эндотелия является поддержание гомеостаза организма человека. На сегодняшний день сформулирована концепция, согласно которой, эндотелиальная дисфункция является центральным звеном в патогенезе сердечно-сосудистых заболеваний (ССЗ). Наличие сахарного диабета (СД) значимо увеличивает риски ССЗ. Часто СД 2 типа (СД2) наблюдается при избыточной массе тела, однако существует популяция лиц с ожирением, у которых в течение длительного времени не развивается СД2.

ЦЕЛЬ

ЦЕЛЬ. Сравнить уровень маркеров эндотелиальной дисфункции в двух группах лиц c ожирением (без СД2 и с СД2), а также оценить влияние приема антидиабетических кардиопротективных препаратов (агонистов рецепторов глюкагоноподобного пептида 1 (арГПП-1) и ингибиторов натрий-глюкозного транспортера 2 (иНГЛТ-2)) на данные маркеры.

МАТЕРИАЛЫ И МЕТОДЫ

МАТЕРИАЛЫ И МЕТОДЫ. В данное исследование были включены 2 группы пациентов с ожирением, одна из которых не имела нарушений углеводного обмена, вторая страдала СД2. Оценивались маркеры эндотелиальной дисфункции: фактор фон Виллебранда, сосудистый эндотелиальный фактор роста А, растворимый Е-селектин (sE-selectin), растворимая молекула межклеточной адгезии-1.

РЕЗУЛЬТАТЫ

РЕЗУЛЬТАТЫ. Получено значимое повышение уровня sЕ-Selectin в группе пациентов с ожирением и СД2 по сравнению с лицами без нарушений углеводного обмена (46,65 [36,23; 66,66] vs 33,05 [22,1; 53,31] нг/мл). Различий по уровням маркеров эндотелиальной дисфункции в подгруппах пациентов с СД2 с уровнем гликированного гемоглобина <8% и >8% обнаружено не было. Также не отмечено влияние назначения кардиопротективных препаратов (иНГЛТ-2 и/или арГПП-1) на исследуемые показатели функции эндотелия у лиц с СД2, по результатам значимых корреляций маркеров эндотелиальной дисфункции не получено.

ЗАКЛЮЧЕНИЕ

ЗАКЛЮЧЕНИЕ. Мы предполагаем, что повышение уровня sE-selectin может являться ранним маркером эндотелиальной дисфункции у лиц с ожирением и СД2.

BACKGROUND

BACKGROUND: One of the function of the endothelium is the maintenance of body's homeostasis. Endothelial dysfunction is known to be profoundly implicated in the pathogenesis of cardiovascular diseases (CVD). The presence of diabetes mellitus significantly increases the risks of CVD. Type 2 diabetes mellitus (T2DM) is often observed in obesity, however, there is a population of people with obesity, who do not develop T2DM for a long time.

AIM

AIM: To compare the level of markers of endothelial dysfunction in two groups of individuals (without T2DM and with T2DM), as well as to evaluate the impact of cardioprotective medication (GPP-1 and SGLT-2) on these markers.

MATERIALS AND METHODS

MATERIALS AND METHODS: We recruited 2 groups of patients with obesity into this study: the 1st group with no carbohydrate metabolism disorders, the 2nd with T2DM. Several markers of endothelial dysfunction were evaluated: human von Willebrand factor (VWF), vascular endothelial growth factor A (VEGF-A), soluble form E-selectin (sE-selectin), soluble intercellular adhesion molecule-1 (sICAM1).

RESULTS

RESULTS: A significant increase in sE-Selectin was seen in the group of patients with obesity and T2DM compared with those without carbohydrate metabolism disorders (46.65 [36.23; 66.66] vs 33.05 [22.1;53.31] ng/ml). There were no differences in the level of markers of endothelial dysfunction in the subgroups of patients with T2DM with HbA1c < 8% and >8%. There was also no effect of cardioprotective drugs (SGLT-2 and / or GPP-1) on any of endothelial dysfunction markers in individuals with T2DM.

CONCLUSION

CONCLUSION: We suggest that an increase in sE-selectin may be an early marker of endothelial dysfunction in obese individuals and T2DM.

эндотелиальная дисфункциясахарный диабет 2 типаожирениеметаболически здоровое ожирениефактор фон Виллебранда (VWF)сосудистый эндотелиальный фактор роста А (VEGF-A)растворимый Е-селектин (sE-selectin)растворимая молекула межклеточной адгезии-1 (sICAM1)endothelial dysfunctiontype 2 diabetes mellitusobesitymetabolically healthy obesityhuman von Willebrand factor (VWF)vascular endothelial growth factor A (VEGF-A)soluble form E-selectin (sE-selectin)soluble intercellular adhesion molecule-1 (sICAM1)Исследование выполнено за счет гранта Российского научного фонда № 19-15-00361, https://rscf.ru/project/19-15-00361/.ReferencesLin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (Lausanne). 2021;(12):147-154. doi: https://doi.org/10.3389/fendo.2021.706978Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol (Lausanne). 2021;(12):147-154. doi: https://doi.org/10.3389/fendo.2021.706978Leitner DR, Fruhbeck G, Yumuk V, et al. Obesity and type 2 diabetes: Two diseases with a need for combined treatment strategies — EASO can lead the way. Obes Facts. 2017;10(5):483-492. doi: https://doi.org/10.1159/000480525Leitner DR, Fruhbeck G, Yumuk V, et al. Obesity and type 2 diabetes: Two diseases with a need for combined treatment strategies — EASO can lead the way. Obes Facts. 2017;10(5):483-492. doi: https://doi.org/10.1159/000480525Ma CX, Ma XN, Guan CH, et al. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74. doi: https://doi.org/10.1186/s12933-022-01516-6Ma CX, Ma XN, Guan CH, et al. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74. doi: https://doi.org/10.1186/s12933-022-01516-6La Sala L, Pontiroli AE. Prevention of diabetes and cardiovascular disease in obesity. Int J Mol Sci. 2020;21(21):8178. doi: https://doi.org/10.3390/ijms21218178La Sala L, Pontiroli AE. Prevention of diabetes and cardiovascular disease in obesity. Int J Mol Sci. 2020;21(21):8178. doi: https://doi.org/10.3390/ijms21218178Bluher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004. doi: https://doi.org/10.1210/endrev/bnaa004Bluher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004. doi: https://doi.org/10.1210/endrev/bnaa004Шестакова М.В., Шестакова Е.А., Скляник И.А., Стафеев Ю.С. Ожирение и сахарный диабет — всегда ли вместе? // Терапевтический архив. — 2022. — Т. 94. — №10. — С. 1131-1135. doi: https://doi.org/10.26442/00403660.2022.10.201880Shestakova MV, Shestakova EA, Sklyanik IA, Stafeev IS. Obesity and diabetes — are they always together? Therapeutic Archive. 2022;94(10):1131-1135. (In Russ.). doi: https://doi.org/10.26442/00403660.2022.10.201880Liu M, Wang P, Xie P, et al. Expression of ICAM-1 and E-selectin in different metabolic obesity phenotypes: discrepancy for endothelial dysfunction. J Endocrinol Invest. 2023;46(11):2379-2389. doi: https://doi.org/10.1007/s40618-023-02094-4Liu M, Wang P, Xie P, et al. Expression of ICAM-1 and E-selectin in different metabolic obesity phenotypes: discrepancy for endothelial dysfunction. J Endocrinol Invest. 2023;46(11):2379-2389. doi: https://doi.org/10.1007/s40618-023-02094-4Mulhem A, Moulla Y, Kloting N, et al. Circulating cell adhesion molecules in metabolically healthy obesity. Int J Obes (Lond). 2021;45(2):331-336. doi: https://doi.org/10.1038/s41366-020-00667-4Mulhem A, Moulla Y, Kloting N, et al. Circulating cell adhesion molecules in metabolically healthy obesity. Int J Obes (Lond). 2021;45(2):331-336. doi: https://doi.org/10.1038/s41366-020-00667-4Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978-3989. doi: https://doi.org/10.1172/JCI129186Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978-3989. doi: https://doi.org/10.1172/JCI129186Coco C, Sgarra L, Potenza MA, et al. Can epigenetics of endothelial dysfunction represent the key to precision medicine in type 2 diabetes mellitus? Int J Mol Sci. 2019;20(12):2949. doi: https://doi.org/10.3390/ijms20122949Coco C, Sgarra L, Potenza MA, et al. Can epigenetics of endothelial dysfunction represent the key to precision medicine in type 2 diabetes mellitus? Int J Mol Sci. 2019;20(12):2949. doi: https://doi.org/10.3390/ijms20122949Montagnani M, Ravichandran LV., Chen H, et al. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol. 2002;16(8):1931-1942. doi: https://doi.org/10.1210/me.2002-0074Montagnani M, Ravichandran LV., Chen H, et al. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol. 2002;16(8):1931-1942. doi: https://doi.org/10.1210/me.2002-0074Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial dysfunction in obesity-induced inflammation: Molecular mechanisms and clinical implications. Biomolecules. 2020;10(2):291. doi: https://doi.org/10.3390/biom10020291Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial dysfunction in obesity-induced inflammation: Molecular mechanisms and clinical implications. Biomolecules. 2020;10(2):291. doi: https://doi.org/10.3390/biom10020291Herder C, Baumert J, Zierer A, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One. 2011;6(6):e19852. doi: https://doi.org/10.1371/journal.pone.0019852Herder C, Baumert J, Zierer A, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS One. 2011;6(6):e19852. doi: https://doi.org/10.1371/journal.pone.0019852Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi: https://doi.org/10.1186/s12933-018-0763-3Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. doi: https://doi.org/10.1186/s12933-018-0763-3Virdis A, Masi S, Colucci R, et al. Microvascular endothelial dysfunction in patients with obesity. Curr Hypertens Rep. 2019;21(4):32. doi: https://doi.org/10.1007/s11906-019-0930-2Virdis A, Masi S, Colucci R, et al. Microvascular endothelial dysfunction in patients with obesity. Curr Hypertens Rep. 2019;21(4):32. doi: https://doi.org/10.1007/s11906-019-0930-2Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61(1):22-32. doi: https://doi.org/10.1016/s1734-1140(09)70004-0Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61(1):22-32. doi: https://doi.org/10.1016/s1734-1140(09)70004-0Khoshbin M, Ahmadi SAY, Cheraghi M, et al. Association of E-Selectin gene polymorphisms and serum E-Selectin level with risk of coronary artery disease in lur population of Iran. Arch Physiol Biochem. 2023;129(2):387-392. doi: https://doi.org/10.1080/13813455.2020.1828481Khoshbin M, Ahmadi SAY, Cheraghi M, et al. Association of E-Selectin gene polymorphisms and serum E-Selectin level with risk of coronary artery disease in lur population of Iran. Arch Physiol Biochem. 2023;129(2):387-392. doi: https://doi.org/10.1080/13813455.2020.1828481Zhang W-J, Cheng J-H, Nie Z-C, et al. Association of E-selectin gene +A561C polymorphism with type 2 diabetes in chinese population. Clin Lab. 2022;68(08/2022):32. doi: https://doi.org/10.7754/Clin.Lab.2021.211045Zhang W-J, Cheng J-H, Nie Z-C, et al. Association of E-selectin gene +A561C polymorphism with type 2 diabetes in chinese population. Clin Lab. 2022;68(08/2022):32. doi: https://doi.org/10.7754/Clin.Lab.2021.211045Hegazy GA, Awan Z, Hashem E, et al. Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications. J Int Med Res. 2020;48(4):030006051989385. doi: https://doi.org/10.1177/0300060519893858Hegazy GA, Awan Z, Hashem E, et al. Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications. J Int Med Res. 2020;48(4):030006051989385. doi: https://doi.org/10.1177/0300060519893858Wiszniak S, Schwarz Q. Exploring the Intracrine Functions of VEGF-A. Biomolecules. 2021;11(1):128 doi: https://doi.org/10.3390/biom11010128Wiszniak S, Schwarz Q. Exploring the Intracrine Functions of VEGF-A. Biomolecules. 2021;11(1):128 doi: https://doi.org/10.3390/biom11010128Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell. 2019;176(6):1248-1264. doi: https://doi.org/10.1016/j.cell.2019.01.021Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell. 2019;176(6):1248-1264. doi: https://doi.org/10.1016/j.cell.2019.01.021Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010;1806(1):108-121. doi: https://doi.org/10.1016/j.bbcan.2010.04.004Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010;1806(1):108-121. doi: https://doi.org/10.1016/j.bbcan.2010.04.004Laakkonen JP, Lahteenvuo J, Jauhiainen S, et al. Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta. Vascul Pharmacol. 2019;112(4):91-101. doi: https://doi.org/10.1016/j.vph.2018.10.005Laakkonen JP, Lahteenvuo J, Jauhiainen S, et al. Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta. Vascul Pharmacol. 2019;112(4):91-101. doi: https://doi.org/10.1016/j.vph.2018.10.005Sun X, Zhang H, Liu J, Wang G. Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Int Med Res. 2019;47(11):5584-5592. doi: https://doi.org/10.1177/0300060519872033Sun X, Zhang H, Liu J, Wang G. Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus. J Int Med Res. 2019;47(11):5584-5592. doi: https://doi.org/10.1177/0300060519872033Saukkonen T, Mutt SJ, Jokelainen J, et al. Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease. Sci Rep. 2018;8(1):12816. doi: https://doi.org/10.1038/s41598-018-31144-8Saukkonen T, Mutt SJ, Jokelainen J, et al. Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease. Sci Rep. 2018;8(1):12816. doi: https://doi.org/10.1038/s41598-018-31144-8Hanefeld M, Appelt D, Engelmann K, et al. Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy [published correction appears in Horm Metab Res. 2016;48(9):620]. Horm Metab Res. 2016;48(8):529-534. doi: https://doi.org/10.1055/s-0042-106295Hanefeld M, Appelt D, Engelmann K, et al. Serum and plasma levels of vascular endothelial growth factors in relation to quality of glucose control, biomarkers of inflammation, and diabetic nephropathy [published correction appears in Horm Metab Res. 2016;48(9):620]. Horm Metab Res. 2016;48(8):529-534. doi: https://doi.org/10.1055/s-0042-106295Hetland ML, Christensen IJ, Lottenburger T, et al. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers. 2008;24(1):1-10. doi: https://doi.org/10.1155/2008/707864Hetland ML, Christensen IJ, Lottenburger T, et al. Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers. 2008;24(1):1-10. doi: https://doi.org/10.1155/2008/707864Yang J, Liu Z. Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne). 2022;13(4):91-101. doi: https://doi.org/10.3389/fendo.2022.816400Yang J, Liu Z. Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne). 2022;13(4):91-101. doi: https://doi.org/10.3389/fendo.2022.816400Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020;15(2):199-210. doi: https://doi.org/10.1007/s11739-019-02253-7Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020;15(2):199-210. doi: https://doi.org/10.1007/s11739-019-02253-7Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res. 2011;128(S1):S3-S7. doi: https://doi.org/10.1016/S0049-3848(12)70002-6Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res. 2011;128(S1):S3-S7. doi: https://doi.org/10.1016/S0049-3848(12)70002-6Alsharidah AS. Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis. Blood Res. 2022;57(2):101-105. doi: https://doi.org/10.5045/br.2022.2021204Alsharidah AS. Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis. Blood Res. 2022;57(2):101-105. doi: https://doi.org/10.5045/br.2022.2021204Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193. doi: https://doi.org/10.1111/j.1538-7836.2006.01949.xVischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4(6):1186-1193. doi: https://doi.org/10.1111/j.1538-7836.2006.01949.xMeigs JB, O'donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006;55(2):530-537. doi: https://doi.org/10.2337/diabetes.55.02.06.db05-1041Meigs JB, O'donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006;55(2):530-537. doi: https://doi.org/10.2337/diabetes.55.02.06.db05-1041Meigs JB, O'Donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes. Diabetes. 2006;55(2):530-537. doi: https://doi.org/10.2337/diabetes.55.02.06.db05-1041Meigs JB, O'Donnell CJ, Tofler GH, et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes. Diabetes. 2006;55(2):530-537. doi: https://doi.org/10.2337/diabetes.55.02.06.db05-1041Zinellu A, Mangoni AA. Systematic review and metaanalysis of the effect of statins on circulating E-selectin, L-selectin, and P-selectin. Biomedicines. 2021;9(11):1707. doi: https://doi.org/10.3390/biomedicines9111707Zinellu A, Mangoni AA. Systematic review and metaanalysis of the effect of statins on circulating E-selectin, L-selectin, and P-selectin. Biomedicines. 2021;9(11):1707. doi: https://doi.org/10.3390/biomedicines9111707Milstone DS, O'Donnell PE, Stavrakis G, et al. et al. E-selectin expression and stimulation by inflammatory mediators are developmentally regulated during embryogenesis. Lab Invest. 2000;80(6):943-954. doi: https://doi.org/10.1038/labinvest.3780097Milstone DS, O'Donnell PE, Stavrakis G, et al. et al. E-selectin expression and stimulation by inflammatory mediators are developmentally regulated during embryogenesis. Lab Invest. 2000;80(6):943-954. doi: https://doi.org/10.1038/labinvest.3780097Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison. J Am Coll Cardiol. 2022;79(18):1849-1857. doi: https://doi.org/10.1016/j.jacc.2022.02.046Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison. J Am Coll Cardiol. 2022;79(18):1849-1857. doi: https://doi.org/10.1016/j.jacc.2022.02.046Qiu S, Cai X, Liu J, et al. Association between circulating cell adhesion molecules and risk of type 2 diabetes: A meta-analysis. Atherosclerosis. 2019;(287):147-154. doi: https://doi.org/10.1016/j.atherosclerosis.2019.06.908Qiu S, Cai X, Liu J, et al. Association between circulating cell adhesion molecules and risk of type 2 diabetes: A meta-analysis. Atherosclerosis. 2019;(287):147-154. doi: https://doi.org/10.1016/j.atherosclerosis.2019.06.908Albertini JP, Valensi P, Lormeau B, et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care. 1998;21(6):1008-1013. doi: https://doi.org/10.2337/diacare.21.6.1008Albertini JP, Valensi P, Lormeau B, et al. Elevated concentrations of soluble E-selectin and vascular cell adhesion molecule-1 in NIDDM. Effect of intensive insulin treatment. Diabetes Care. 1998;21(6):1008-1013. doi: https://doi.org/10.2337/diacare.21.6.1008Palella E, Cimino R, Pullano SA, et al. Laboratory parameters of hemostasis, adhesion molecules, and inflammation in type 2 diabetes mellitus: Correlation with glycemic control. Int J Environ Res Public Health. 2020;17(1):300. doi: https://doi.org/10.3390/ijerph17010300Palella E, Cimino R, Pullano SA, et al. Laboratory parameters of hemostasis, adhesion molecules, and inflammation in type 2 diabetes mellitus: Correlation with glycemic control. Int J Environ Res Public Health. 2020;17(1):300. doi: https://doi.org/10.3390/ijerph17010300Yue W, Li Y, Ou D, Yang Q. The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. 2019;71(9):1347-1354. doi: https://doi.org/10.1002/iub.2046Yue W, Li Y, Ou D, Yang Q. The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2. IUBMB Life. 2019;71(9):1347-1354. doi: https://doi.org/10.1002/iub.2046Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050-2068. doi: https://doi.org/10.7150/ijbs.59965Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050-2068. doi: https://doi.org/10.7150/ijbs.59965Wei R, Wang W, Pan Q, Guo L. Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;(13):147-154. doi: https://doi.org/10.3389/fendo.2022.826604Wei R, Wang W, Pan Q, Guo L. Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;(13):147-154. doi: https://doi.org/10.3389/fendo.2022.826604

The authors declare that there are no conflicts of interest present.